Phase 2Recruiting
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC (Industry)
- Enrolment
- 200 planned
- Conditions
- Multiple System Atrophy
- Interventions
- TEV-56286
- Ages
- adults, older adults
- Registry
- NCT07197866
From the registry
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Primary outcomes
- Number of participants experiencing an adverse event
- Number of participants who withdrew from the trial due to an adverse event